With Profs. R.C. Robbins and J.C. Wu, and Andrew Lee, co-founded Stem Cell Theranostics; With Andrew Lee, co-founded Stanford's StartX Med incubator.
Awards
Fortune 40 under 40, Silicon Valley Top 100 Innovators and Disruptors, 25 Coolest Women in Silicon Valley, Business Insider Most Powerful Millennials under 35
Divya Nag (born c. 1991[not verified in body]) is an American biotechnology entrepreneur and biologist with a cardiology emphasis that has, since 2014, been employed by Apple Health, as of 2016 involved as a team lead in Special Projects.
At Apple, as of 2016, Nag was leading the team that design such tools as the open-source developer toolbox, ResearchKit, and Apple's patient alert and communication tool, CareKit, products that ease communication between healthcare researchers, professionals, and patients.[6][7]
Nag was born in 1991 in California,[citation needed] and grew up in El Dorado County.[8] Her parents immigrated to the United States from Jaipur, India, before she was born.[8] Nag's father, Harish Nag, is a software program manager at Intel Folsom;[8] in interview, Nag has stated, "My dad always taught me, 'If you’re the smartest person in the room, leave.'"[8]
During her time at Mira Loma, Nag had a desire to work alongside scientists, so she contacted many at the University of California, Davis, and was offered an internship by one, Alexandra Navrotsky, with whom she "researched how microscopic particles... could help stop forest fires...", Nag stating, "We found if we could increase the quartz concentration in the soil, it can absorb a lot more heat and you require a much higher temperature for the fire to begin", a practical result that Nag told her interviewer was being applied in fire management.[8]
At Stanford
Nag was accepted to Stanford University in 2009 to pursue an undergraduate degree in bioengineering and medical anthropology.[9][dead link] She began research in the lab of Joseph C. Wu,[when?] studying stem cells, their induction, and their potential use in transplantation.[citation needed] She also explored various aspects of cardiovascular disease.[clarification needed][independent source needed] Nag began to work alongside Wu and Stanford professor Robert Robbins and Wu laboratory MD-PhD trainee in Chemical Systems Biology, Andrew Lee, to create a drug testing platform where rapid assessment of drug candidate safety and efficacy could be performed on stem cell-derived human heart tissue, with the aim of expediting drug discovery.[1][2][independent source needed][4][5][verification needed] With the more senior Robbins, Wu, and Lee, Nag participated in the launch of the company Stem Cell Theranostics (various sources state 2011-2013 founding dates), to begin commercializing the Wu and Robbins technologies.[1][2][10][11][12][3][5]
One year later, Nag co-founded StartX Med with Andrew Lee,[citation needed] a spin-off of the accelerator program StartX at Stanford in order to help students like herself begin the process of biotechnology innovation and healthcare entrepreneurship.[citation needed]
By 2012, Nag was heavily involved in both Stem Cell Theranostics and StartX Med so she decided to discontinue her studies at Stanford, at the age of 20.[13]
While a Stanford undergraduate, Nag, working with physician scientists Robert C. Robbins and Joseph C. Wu, and Stanford MD-PhD trainee Andrew Lee, helped found Stem Cell Theranostics, a company whose aim has been to develop patient-specific stem cells for use in a drug discovery platform; dates of founding vary between 2011 and 2013.[14][1][2][3][4][5] Stem Cell Theranostics is a biotechnology company that pioneered the use of skin cell-derived stem cells to use in drug discovery platforms.[8][bettersourceneeded] Specifically, they would take skin cells and convert them to stem cells and then re-differentiate them into heart cells through the addition of transcription factors.[citation needed] Since the heart cells, now being grown in a dish, are derived from a patient, they contain genetic profile and thus drugs can be tested in a patient specific manner.[citation needed] The motivation behind the company lies in the fact that most drugs do not make it to the final stages of clinical trials due to cardiovascular effects and further, most drugs that are recalled after passing the final stages, are recalled due to negative effects on the cardiovascular system.[citation needed] The company wanted a cheap and fast way to test the effects of a drug on human cells, instead of in mice, so speed up the drug discovery process and bring harmless and specific treatments to patients as quickly as possible.[citation needed] As Nagy states in a YouTube video that was accessed for her Fierce Biotech "Top Women in Medical Devices 2014" accolade, "We've tested every single drug that has been pulled from market due to cardiotoxicity and have shown with 100% accuracy that we could have spotted it on day one of its conception."[15]
The Stem Cell Theranostics website became inactive some time after April 2016,[1] and as of December 2025, the "clinical trial in a dish" was being offered by the distinct Joseph C. Wu-led company, Greenstone Biosciences.[16][17]
StartX Med
Nag and Wu laboratory colleague Andrew Lee co-founded StartX Med at Stanford University in 2012.[citation needed] StartX Med is the part of the Stanford StartX organization that supports students in their path towards innovating and developing startups through Stanford, specifically in the healthcare and medical areas.[18] She was inspired by her own experiences starting Stem Cell Theranostics as she saw added hurdles in starting a healthcare startup compared to the typical technology startup that StartX supported.[8] She wanted to help students navigate their way through finding laboratories and FDA approval as she had to for her company as well as create a collaborative environment for students interested in starting companies in the healthcare sector.[citation needed] StartX Med has now helped over 500 health technology companies, raised over $1 billion in aggregate, and partnered with top 10 pharmaceutical companies to bring ideas into practice.[citation needed]
In 2014, Nag was recruited to work at Apple in their Special Projects unit, to "innovate novel ways to make healthcare data easily usable by both patients and researchers".[citation needed] There, as of 2016, she led the team that created ResearchKit, a developer toolbox (open-source) that functions alongside Apple’s health data storage and sharing tool, HealthKit, such that researchers and physicians can create iPhone apps to gather data for medical research, rather than relying on physical access by patients to research facilities.[6][7] Applications as of 2016 included work on autism, concussion, diabetes, and Parkinson’s disease.[6] Nag's work has extended to Apple's patient alert and communication tool, CareKit, to "brin[g]... data-sharing... to the patient-physician relationship".[6] CareKit tools allow automatic alerts from doctors to patients (regarding medications, exercise, etc.), and provides a communication path from a patient to doctors to "continual[ly] update... their condition".[6]
Gurman, Mark (April 20, 2014). "Apple Adds Rising Star With Background in FDA Approvals and Product Testing to Medical Team". 9to5Mac.com. Retrieved May 16, 2020. [Entire SCT company information, this source:] Nag made her entry into the medical technology world earlier this decade by co-founding Stem Cell Theranostics, a company that focuses on technologies for testing new medicines for the market and how the drugs will affect patients. Nag also participated in the Stanford-based StartX, an 'accelerator' for medical technology-focused startups.
References
12345SCT Staff (April 2, 2016). "Stem Cell Theranostics / Who We Are". SCTheranostics.com. Menlo Park, CA: Stem Cell Theranostics (SCT). Archived from the original on April 2, 2016. Retrieved December 5, 2025. Stem Cell Theranostics (SCT) is a Silicon Valley Biotechnology Company that was launched in 2013 to commercialize the breakthroughs perfected at Stanford University School of Medicine for use of patient-specific stem cells in personalized medicine. SCT's core technology focuses on the generation and use of patient-specific stem cells in drug screening and therapeutic development. Our initial product, a "Clinical Trial in a Dish" drug screening platform, was developed at Stanford over the past decade by SCT's world-renowned founders—Dr. Joseph Wu, Dr. Robert Robbins, and Dr. Andrew Lee. The preceding URL is that of the latest archived version of the company's website.
1234SCT Staff (June 9, 2013). "Stem Cell Theranostics/About—Founders". SCTheranostics.com. Menlo Park, CA: Stem Cell Theranostics (SCT). Archived from the original on June 9, 2013. Retrieved December 5, 2025. SCT was formally launched in 2013 by professors Bobby Robbins and Joseph Wu, graduate student Andrew Lee, and undergraduate student researcher Divya Nag. / Founders [biographies, highlighted] / Robert Robbins, MD... / Joseph Wu, MD, PhD... / Andrew Lee... The preceding URL is that of the earliest archived version of the company's website.
123Tansey, Bernadette (May 2, 2014). "The Experiment Begins: Y Combinator Admits First Biotech Startups". Xconomy (Xconomy.com). London, England: Informa Connect Ltd. Archived from the original on November 11, 2014. Retrieved December 5, 2025. Stem Cell Theranostics... was founded in 2013 to commercialize stem cell research from the labs of two professors at the Stanford University School of Medicine. Its co-founders include a former Stanford undergraduate, Divya Nag, and a Stanford post-doctoral student,[sic.] Andrew Lee, who also co-founded StartX Med, the student-run campus incubator for biomedical entrepreneurs.
↑The comtemporary Stanford news reports that follow concern the work of Wu, and postdoctoral scholars Ning Sun, Feng Lan, and Ping Liang, and graduate student Andrew Lee. See Conger (April 18, 2012) and Conger (January 3, 2013), op. cit.
12"Divya Nag". Fortune. Retrieved December 4, 2025. By the time Nag had joined Apple, at age 23, she had dropped out of Stanford, founded a stem-cell research startup, and begun a medical investment accelerator. Now she oversees Apple's ambitious ResearchKit and CareKit programs that encourage developers to build health-related apps. If Apple succeeds, it could transform clinical trials from isolated events at hospitals to ongoing studies that capture vital signs from omnipresent sensors. Nag's personal goal is no less ambitious. "I want to put people in charge of their health," she says. "It's not about living with a specific disease or condition. It's about living. Full stop."
↑Contemporary technology news reporting in this period, in particular, pieces highlighting Nag's accomplishment for her age, sometimes state Nag as a founder or a principal co-founder; however, the archived company websites from 2013-2016, while mentioning Nag, clearly emphasize the earlier, deeper, more longterm roles of Robbins, Wu, and Lee. See SCT Staff (June 9, 2013) and SCT Staff (April 2, 2016), op. cit., and other citations following.
↑GB Staff (December 5, 2025). "Clinical Trial in a Dish". GreenstoneBio.com/. Palo Alto, CA: Greenstone Biosciences (GB). Retrieved December 5, 2025. At Greenstone Biosciences, we are redefining how new medicines are developed with our Clinical Trial in a Dish platform. Traditional preclinical models often fail to capture the complexity of human biology, leaving gaps that only emerge in costly and time-intensive clinical trials. Our approach changes that by bringing clinical trial design into the laboratory—before a single patient is enrolled. / Using patient-derived induced pluripotent stem cells (iPSCs), we recreate the cellular environments of real patient populations. These models incorporate genetic diversity, demographic variables, and clinical backgrounds... .
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
